Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1337 • ACR Convergence 2021
Long-Term Safety Data for IL-12/23 Inhibitor (Ustekinumab) or Tumor Necrosis Factor Inhibitor in Patients with Psoriatic Arthritis from a Real-World Study
Stefan Siebert¹, Paul Bergmans², Kurt de Vlam³, Elisa Gremese⁴, Beatriz Joven-Ibáñez⁵, Tatiana Korotaeva⁶, Wim Noël⁷, Michael Nurmohamed⁸, Petros Sfikakis⁹, Elke Theander¹⁰, Laure Gossec¹¹ and Josef Smolen¹², ¹University of Glasgow, Glasgow, United Kingdom, ²Janssen-Cilag BV, Breda, Netherlands, ³University Hospitals Leuven, Leuven, Belgium, ⁴Fondazione Policlinico A Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, ⁵University Hospital 12 de Octubre, Madrid, Spain, ⁶VA Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁷Janssen Pharmaceutica, HEMAR Department, Beerse, Belgium, ⁸Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ⁹National Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ¹⁰Janssen Cilag, Lund, Sweden, ¹¹Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, ¹²Medical University of Vienna, Vienna, Austria
Background/Purpose: Psoriasis and PsA are associated with multiple comorbidities such as cardiovascular disease and metabolic syndrome. These comorbidities may render patients prone to developing adverse…
Abstract Number: 1354 • ACR Convergence 2021
Differences in Real-World Patient Characteristics of 8921 Patients with Psoriasis with and Without Comorbid Psoriatic Arthritis Using the UK BADBIR Database
William Tillett¹, Alexis Ogdie², Patricia Gorecki³ and Alun Passey⁴, ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²University of Pennsylvania, Philadelphia, PA, ³Janssen Medical Affairs, London, United Kingdom, ⁴Janssen Real World Evidence, HEMAR EMEA, High Wycombe, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis (PsO) and multiple comorbidities.1 Approximately one-third of patients with PsO develop PsA during…
Abstract Number: 1722 • ACR Convergence 2021
Risk of Pre-eclampsia and Impact of Disease Activity and Anti-rheumatic Treatment in Women with Rheumatoid Arthritis, Axial Spondylarthritis, and Psoriatic Arthritis – A Collaborative Matched Cohort Study from Sweden and Denmark
Anne Emilie Secher¹, Karin Hellgren², Bente Glintborg³, Ane Rom⁴, Merete Hetland⁵ and Fredrik Granath², ¹COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, Frederiksberg, Denmark, ²Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ³COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, Glostrup, Denmark, ⁴The Juliane Marie Centre, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Denmark, ⁵DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark
Background/Purpose: Pre-eclampsia is a pregnancy-related syndrome with potentially fatal outcomes. In RA, high disease activity has been associated to adverse pregnancy outcomes such as preterm…
Abstract Number: 1789 • ACR Convergence 2021
Prediction of Psoriatic Arthritis in Patients with Psoriasis Using DNA Methylation Profiles
Omar Cruz Correa¹, Remy Pollock¹, Rohan Machhar² and Dafna Gladman³, ¹University Health Network, Toronto, ON, Canada, ²Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) poses an immense clinical burden with significantly increased morbidity and mortality risk compared to psoriasis alone. PsA may develop in 30%…
Abstract Number: 1806 • ACR Convergence 2021
Designing a Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Guselkumab (TREMFYA®/sup>) Dosing Interval in Psoriatic Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibition
Alexis Ogdie-Beatty¹, Joseph Merola², Philip Mease³, Christopher Ritchlin⁴, Jose Scher⁵, Daphne Chan⁶, Soumya Chakravarty⁷, Wayne Langholff⁸, Olivia Choi⁹, Yevgeniy Krol⁹, Katelyn Rowland⁹ and Alice Gottlieb¹⁰, ¹University of Pennsylvania, Philadelphia, PA, ²Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁴Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ⁵New York University School of Medicine, New York, NY, ⁶Janssen Scientific Affairs, LLC, Spring House, PA, ⁷Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, ⁸Janssen Research & Development, LLC, Spring House, PA, ⁹Janssen Scientific Affairs, LLC, Horsham, PA, ¹⁰Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are frequently chosen as the first biologic therapy for patients (pts) with PsA, though a sizeable proportion of pts…
Abstract Number: 1824 • ACR Convergence 2021
Secukinumab Treatment Provides Sustained Resolution of Enthesitis at Individual Joints Through 52 Weeks in a Phase 3b, Double-Blind, Randomized, Active-Controlled Study
Gurjit Kaeley¹, Georg Schett², Philip Conaghan³, Dennis McGonagle⁴, Frank Behrens⁵, Philippe Goupille⁶, Corine Gaillez⁷, Bhumik Parikh⁸, Xiangyi Meng⁸ and Catherine Bakewell⁹, ¹University of Florida, Jacksonville, FL, ²Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴University of Leeds, Leeds, United Kingdom, ⁵Rheumatology and Fraunhofer ITMP - Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, ⁶University hospital of Tours, Rheumatology department, Tours, France, ⁷Novartis Pharma AG, Basel, Switzerland, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Intermountain Healthcare Medical Group, Salt Lake City, UT
Background/Purpose: Enthesitis is a key musculoskeletal manifestation of psoriatic arthritis (PsA). In the double-blind, head-to-head EXCEED study (NCT02745080), although the primary endpoint of superiority of…
Abstract Number: 1945 • ACR Convergence 2021
Efficacy of Upadacitinib on Psoriatic Arthritis with Axial Involvement Defined by Investigator Assessment and PRO-Based Criteria: Results from Two Phase 3 Studies
Xenofon Baraliakos¹, Roberto Ranza², Andrew Ostor³, Francesco Ciccia⁴, Laura Coates⁵, Simona Rednic⁶, Jessica Walsh⁷, Tianming Gao⁸, Apinya Lertratanakul⁸, In-Ho Song⁸, Fabiana Ganz⁸, Kevin Douglas⁸ and Atul Deodhar⁹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlandia, MG, Brazil, ³Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia, ⁴University of Campania Luigi Vanvitelli, Napoli, Italy, ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁶Emergency Clinical County Hospital, Rheumatology and Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania, ⁷Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ⁸AbbVie Inc., North Chicago, IL, ⁹Oregon Health & Science University, Portland, OR
Background/Purpose: Patients with PsA and axial involvement have higher disease activity and greater reductions in quality of life;1 however, there are no accepted criteria for…
Abstract Number: 0135 • ACR Convergence 2021
Comparing Rheumatoid Arthritis (RA), Psoriatic Arthritis (PA) and Systemic Lupus Erythematosus (SLE) Total Cost of Care (TCC) in Those with Optimally Managed Depression to Those with Sub-optimally Managed Depression
Joseph Couto¹, Elisea Avalos-Reyes², Amanda McCarthy³, Olga Matlin⁴, Michele Hamburger⁵, Gerard Maher⁶ and Kjel Johnson¹, ¹CVS Health, Lincoln, RI, ²CVS Health, Irving, TX, ³CVS Health, Greensboro, GA, ⁴CVS Health, Northbrook, IL, ⁵Frances Hamburger Institute, Hauppauge, NY, ⁶Frances Hamburger Institute, Hauppaugue, NY
Background/Purpose: Rheumatic diseases (RD) are characterized by systemic signs and symptoms, including articular and extra-articular manifestations. Three common forms of RDs are RA, PsA and…
Abstract Number: 0490 • ACR Convergence 2021
Biomarker Changes with Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in PsA: Effects on Disease Markers and Tyrosine Kinase 2‒ versus Janus Kinase 1/2/3‒mediated Pathways
Oliver FitzGerald¹, Dafna Gladman², Philip Mease³, Christopher Ritchlin⁴, Josef Smolen⁵, Lu Gao⁶, Sarah Hu⁶, Miroslawa Nowak⁶, Subhashis Banerjee⁶, Ian Catlett⁶ and Xiang Guo⁶, ¹Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁴Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ⁵Medical University of Vienna, Vienna, Austria, ⁶Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Deucravacitinib is a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action that has demonstrated efficacy in patients (pts)…
Abstract Number: 0944 • ACR Convergence 2021
A Characterization of the Gut and Cutaneous Microbiome of Monozygotic Twins Discordant for Psoriatic Disease
Julia Manasson¹, Matthew Stapylton², Rhina Medina¹, Rochelle Castillo³, Parvathy Vasudevanpillai Girija¹, Adriana Heguy¹, Carles Ubeda⁴, Mid-Atlantic Twin Registry (MATR)⁵, Jose Clemente² and Jose Scher¹, ¹New York University School of Medicine, New York, NY, ²Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, ³NYU Langone Health, New York, NY, ⁴La Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, Valencia, Spain; CIBERESP, Madrid, Spain, ⁵Virginia Commonwealth University, Richmond, VA
Background/Purpose: Psoriasis (PsO) is an inflammatory, immune-mediated skin disorder affecting ~3% of the population worldwide. It is associated with multiple comorbidities, including psoriatic arthritis (PsA),…
Abstract Number: 1319 • ACR Convergence 2021
Cardiovascular Risk Reclassification According to Six Traditional Cardiovascular Risk Algorithms and a Carotid Ultrasound in Psoriatic Arthritis Patients
Natalia Guajardo-Jauregui, Iris Colunga-Pedraza, Jose Azpiri-Lopez, Dionicio Galarza-Delgado, Alejandra Rodriguez-Romero, Diana Flores-Alvarado, Alejandro Meza-Garza, Julieta Loya-Acosta, Jesus Cardenas-de La Garza, Salvador Lugo-Perez, Octavio Ilizaliturri-Guerra, Gisela Garcia-Arellano and Jessica Castillo-Treviño, Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico
Background/Purpose: Patients with psoriatic arthritis (PsA) have a higher risk of developing a cardiovascular (CV) event than the general population. This could be attributed to…
Abstract Number: 1338 • ACR Convergence 2021
Bimekizumab in Patients with Psoriatic Arthritis: 3-Year Results for Overall and Tumor Necrosis Factor Inhibitor (TNFi)-Naïve Populations from a Phase 2b Open-Label Extension Study
Philip Mease¹, Atul Deodhar², Joseph Merola³, Iain McInnes⁴, Deepak Assudani⁵, Rajan Bajracharya⁵, Jason Coarse⁶, Barbara Ink⁷ and Georg Schett⁸, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Oregon Health & Science University, Portland, OR, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Raleigh, NC, ⁷UCB Celltech, Slough, UK, Slough, United Kingdom, ⁸Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, and has demonstrated clinical improvements in joint and skin outcomes…
Abstract Number: 1355 • ACR Convergence 2021
Psoriatic Arthritis Incidence Among Patients Receiving Biologic Medications for Psoriasis; A Nested Case Control Study
Iftach Sagy¹, Yael Shalev Rosenthal², Naama Schwartz² and Lev Pavlovsky², ¹Clinical Research Center, Soroka University Medical Center, Beer Sheva and Ben Gurion University of the Negev, DVIRA, Israel, ²Rabin Medical Center, Petach Tikva, Israel
Background/Purpose: The objective of this study was to investigate the effect of biological treatments for psoriasis on the incidence of psoriatic arthritis.Methods: A retrospective cohort…
Abstract Number: 1738 • ACR Convergence 2021
Uveitis Status in Patients with Ankylosing Spondylitis or Psoriatic Arthritis Under Secukinumab Treatment – Real World Data from a German Observational Study
Uta Kiltz¹, Jan Brandt-Jrgens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵, Annika Boas⁶ and Hans-Peter Tony⁷, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Ambulantes Rheumazentrum Erfurt, Erfurt, Germany, ⁴Department for Rheumatology and Immunology, Hannover Medical University, Hannover, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Novartis Pharma GmbH, Nuernberg, Germany, ⁷Universitätsklinikum Würzburg, Wuerzburg, Germany
Background/Purpose: Uveitis is a well-known non-musculoskeletal manifestation of spondyloarthropathies. Patients typically suffer from blurred vision, pain, and photophobia and have an increased risk of ocular…
Abstract Number: 1790 • ACR Convergence 2021
Regional Differences in Clinical Characteristics and Treatment of Psoriatic Arthritis with Axial Involvement: Results from the Cross Sectional International ASAS PerSpA Study
Haruki Sawada¹, Mitsumasa Kishimoto², Kurisu Tada¹, Gautam Deshpande³, Daiki Kobayashi⁴, Keisuke Ono⁵, Yoshinori Taniguchi⁶, Ayako Hirata⁷, Hideto Kameda⁷, Shigeyoshi Tsuji⁸, Yuko Kaneko⁹, Tadashi Okano¹⁰, Yoichiro Haji¹¹, Hiroaki Dobashi¹², Akimichi Morita¹³, Akihiko Asahina¹⁴, Masato Okada¹⁵, Tetsuya Tomita¹⁶, Diego Benavent¹⁷, Chamaida Plasencia-Rodríguez¹⁸, Victoria Navarro-Compán¹⁷, Clementina López Medina¹⁹, Anna Molto²⁰, Désirée van der Heijde²¹, Maxime Dougados²² and Naoto Tamura¹, ¹Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan, ²Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Yokohama, Japan, ³Department of General Internal Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan, ⁴Department of Internal Medicine, St. Luke's International Hospital, Tokyo, Japan, ⁵Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁶Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Nankoku, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, ⁸Department of Orthopedics and Rheumatology, National Hospital Organization Osaka Minami Medical Center, Osaka, Japan, ⁹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁰Department of Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ¹¹Department of Rheumatology, Daido Hospital, Nagoya, Japan, ¹²Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ¹³Department of Geriatric and Environmental Dermatology, Nagoya City University, Nagoya, Japan, ¹⁴Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan, ¹⁵Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, ¹⁶Department of Orthopaedic Biomaterial Science, Osaka University Graduate School of Medicine, Suita Osaka, Japan, ¹⁷Rheumatology service, Hospital Universitario La Paz-IdiPaz, madrid, Spain, ¹⁸Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Rheumatology, La Paz University Hospital, Madrid, Spain, ¹⁹Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France, ²⁰Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France, ²¹Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ²²Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France
Background/Purpose: Psoriatic arthritis (PsA) shares genetic and clinical features with other forms of spondyloarthritis (SpA). However, no studies have evaluated regional differences regarding characteristics of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].